EcoDrugPlus

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSOGAG00000009361
Gene Symbol: NAMPT
4 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nischarin

Ensembl ID : ENSOGAG00000004076
Gene Symbol: NISCH
2 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nitric Oxide Synthase 2

Ensembl ID : ENSOGAG00000008862
Gene Symbol: NOS2
4 Cross references
163 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Notch Receptor 1

Ensembl ID : ENSOGAG00000015908
Gene Symbol: NOTCH1
4 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Notch Receptor 3

Ensembl ID : ENSOGAG00000006680
Gene Symbol: NOTCH3
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSOGAG00000012840
Gene Symbol: NFKB1
2 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSOGAG00000016379
Gene Symbol: NFKB2
2 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSOGAG00000012593
Gene Symbol: NR1H2
2 Cross references
305 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSOGAG00000012410
Gene Symbol: NR1H3
4 Cross references
391 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSOGAG00000007874
Gene Symbol: NR1H4
4 Cross references
387 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOGAG00000003356
Gene Symbol: NR3C1
4 Cross references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSOGAG00000014008
Gene Symbol: NR3C2
4 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).